Pub Date : 2014-01-01Epub Date: 2014-01-09DOI: 10.1155/2014/170634
Linda Vona-Davis, David P Rose, Vijaya Gadiyaram, Barbara Ducatman, Gerald Hobbs, Hannah Hazard, Sobha Kurian, Jame Abraham
Breast cancer patients in rural Appalachia have a high prevalence of obesity and poverty, together with more triple-negative phenotypes. We reviewed clinical records for tumor receptor status and time to distant metastasis. Body mass index, tumor size, grade, nodal status, and receptor status were related to metastatic patterns. For 687 patients, 13.8% developed metastases to bone (n = 42) or visceral sites (n = 53). Metastases to viscera occurred within five years, a latent period which was shorter than that for bone (P = 0.042). More women with visceral metastasis presented with grade 3 tumors compared with the bone and nonmetastatic groups (P = 0.0002). There were 135/574 women (23.5%) with triple-negative breast cancer, who presented with lymph node involvement and visceral metastases (68.2% versus 24.3%; P = 0.033). Triple-negative tumors that metastasized to visceral sites were larger (P = 0.007). Developing a visceral metastasis within 10 years was higher among women with triple-negative tumors. Across all breast cancer receptor subtypes, the probability of remaining distant metastasis-free was greater for brain and liver than for lung. The excess risk of metastatic spread to visceral organs in triple-negative breast cancers, even in the absence of positive nodes, was combined with the burden of larger and more advanced tumors.
{"title":"Breast cancer pathology, receptor status, and patterns of metastasis in a rural appalachian population.","authors":"Linda Vona-Davis, David P Rose, Vijaya Gadiyaram, Barbara Ducatman, Gerald Hobbs, Hannah Hazard, Sobha Kurian, Jame Abraham","doi":"10.1155/2014/170634","DOIUrl":"https://doi.org/10.1155/2014/170634","url":null,"abstract":"<p><p>Breast cancer patients in rural Appalachia have a high prevalence of obesity and poverty, together with more triple-negative phenotypes. We reviewed clinical records for tumor receptor status and time to distant metastasis. Body mass index, tumor size, grade, nodal status, and receptor status were related to metastatic patterns. For 687 patients, 13.8% developed metastases to bone (n = 42) or visceral sites (n = 53). Metastases to viscera occurred within five years, a latent period which was shorter than that for bone (P = 0.042). More women with visceral metastasis presented with grade 3 tumors compared with the bone and nonmetastatic groups (P = 0.0002). There were 135/574 women (23.5%) with triple-negative breast cancer, who presented with lymph node involvement and visceral metastases (68.2% versus 24.3%; P = 0.033). Triple-negative tumors that metastasized to visceral sites were larger (P = 0.007). Developing a visceral metastasis within 10 years was higher among women with triple-negative tumors. Across all breast cancer receptor subtypes, the probability of remaining distant metastasis-free was greater for brain and liver than for lung. The excess risk of metastatic spread to visceral organs in triple-negative breast cancers, even in the absence of positive nodes, was combined with the burden of larger and more advanced tumors. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"170634"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/170634","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32115233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-04-01DOI: 10.1155/2014/315378
Brian Cox, Chih-Wei Liu, Mary J Sneyd, Claire M Cameron
Background. Non-Hodgkin lymphoma (NHL) incidence rates have increased considerably in New Zealand. Methods. Incidence and mortality rates for NHL from 1981 to 2010 were calculated. Trends in age-specific rates were analysed and age-period-cohort models fitted to explore generation-specific changes in incidence and mortality. Results. NHL incidence increased by 67% for men and 74% for women between the 1981-1985 and 2006-2010 time periods in New Zealand. For women born about 1936 and men born about 1946, NHL incidence and mortality have diverged suggesting an improved prognosis for recent generations. Conclusion. The strong generation effects suggest that an exposure before 25 years of age is of major importance in determining the lifetime risk of NHL in New Zealand. NHL incidence rates in New Zealand will continue to increase in the future and probably more in females than males, as generations with increased risk age. Current hypotheses for the cause of NHL do not explain the trends observed. A decline in the prevalence of a protective factor may have also contributed to these trends. Examination of trends for subtypes of NHL and innovative testable hypotheses that may explain these trends are needed.
{"title":"Epidemic of non-hodgkin lymphoma in new zealand remains unexplained.","authors":"Brian Cox, Chih-Wei Liu, Mary J Sneyd, Claire M Cameron","doi":"10.1155/2014/315378","DOIUrl":"https://doi.org/10.1155/2014/315378","url":null,"abstract":"<p><p>Background. Non-Hodgkin lymphoma (NHL) incidence rates have increased considerably in New Zealand. Methods. Incidence and mortality rates for NHL from 1981 to 2010 were calculated. Trends in age-specific rates were analysed and age-period-cohort models fitted to explore generation-specific changes in incidence and mortality. Results. NHL incidence increased by 67% for men and 74% for women between the 1981-1985 and 2006-2010 time periods in New Zealand. For women born about 1936 and men born about 1946, NHL incidence and mortality have diverged suggesting an improved prognosis for recent generations. Conclusion. The strong generation effects suggest that an exposure before 25 years of age is of major importance in determining the lifetime risk of NHL in New Zealand. NHL incidence rates in New Zealand will continue to increase in the future and probably more in females than males, as generations with increased risk age. Current hypotheses for the cause of NHL do not explain the trends observed. A decline in the prevalence of a protective factor may have also contributed to these trends. Examination of trends for subtypes of NHL and innovative testable hypotheses that may explain these trends are needed. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"315378"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/315378","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32316731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-09-21DOI: 10.1155/2014/437971
Amal S Ibrahim, Hussein M Khaled, Nabiel Nh Mikhail, Hoda Baraka, Hossam Kamel
Background. This paper aims to present cancer incidence rates at national and regional level of Egypt, based upon results of National Cancer Registry Program (NCRP). Methods. NCRP stratified Egypt into 3 geographical strata: lower, middle, and upper. One governorate represented each region. Abstractors collected data from medical records of cancer centers, national tertiary care institutions, Health Insurance Organization, Government-Subsidized Treatment Program, and death records. Data entry was online. Incidence rates were calculated at a regional and a national level. Future projection up to 2050 was also calculated. Results. Age-standardized incidence rates per 100,000 were 166.6 (both sexes), 175.9 (males), and 157.0 (females). Commonest sites were liver (23.8%), breast (15.4%), and bladder (6.9%) (both sexes): liver (33.6%) and bladder (10.7%) among men, and breast (32.0%) and liver (13.5%) among women. By 2050, a 3-fold increase in incident cancer relative to 2013 was estimated. Conclusion. These data are the only available cancer rates at national and regional levels of Egypt. The pattern of cancer indicated the increased burden of liver cancer. Breast cancer occupied the second rank. Study of rates of individual sites of cancer might help in giving clues for preventive programs.
{"title":"Cancer incidence in egypt: results of the national population-based cancer registry program.","authors":"Amal S Ibrahim, Hussein M Khaled, Nabiel Nh Mikhail, Hoda Baraka, Hossam Kamel","doi":"10.1155/2014/437971","DOIUrl":"https://doi.org/10.1155/2014/437971","url":null,"abstract":"<p><p>Background. This paper aims to present cancer incidence rates at national and regional level of Egypt, based upon results of National Cancer Registry Program (NCRP). Methods. NCRP stratified Egypt into 3 geographical strata: lower, middle, and upper. One governorate represented each region. Abstractors collected data from medical records of cancer centers, national tertiary care institutions, Health Insurance Organization, Government-Subsidized Treatment Program, and death records. Data entry was online. Incidence rates were calculated at a regional and a national level. Future projection up to 2050 was also calculated. Results. Age-standardized incidence rates per 100,000 were 166.6 (both sexes), 175.9 (males), and 157.0 (females). Commonest sites were liver (23.8%), breast (15.4%), and bladder (6.9%) (both sexes): liver (33.6%) and bladder (10.7%) among men, and breast (32.0%) and liver (13.5%) among women. By 2050, a 3-fold increase in incident cancer relative to 2013 was estimated. Conclusion. These data are the only available cancer rates at national and regional levels of Egypt. The pattern of cancer indicated the increased burden of liver cancer. Breast cancer occupied the second rank. Study of rates of individual sites of cancer might help in giving clues for preventive programs. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"437971"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/437971","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32757633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-05-26DOI: 10.1155/2014/469251
Carol A Parise, Vincent Caggiano
Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor grade. Methods. We identified 123,780 cases of stages 1-3 primary female invasive breast cancer from California Cancer Registry. The surrogate classification was derived using ER/PR/HER2 and tumor grade. Kaplan-Meier survival analysis and Cox proportional hazards modeling were used to assess differences in survival and risk of mortality for the ER/PR/HER2 subtypes and surrogate classification within each stage. Results. The luminal B/HER2- surrogate classification had a higher risk of mortality than the luminal B/HER2+ for all stages of disease. There was no difference in risk of mortality between the ER+/PR+/HER2- and ER+/PR+/HER2+ in stage 3. With one exception in stage 3, the ER-negative subtypes all had an increased risk of mortality when compared with the ER-positive subtypes. Conclusions. Assessment of survival using ER/PR/HER2 illustrates the heterogeneity of HER2+ subtypes. The surrogate classification provides clear separation in survival and adjusted mortality but underestimates the wide variability within the subtypes that make up the classification.
{"title":"Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.","authors":"Carol A Parise, Vincent Caggiano","doi":"10.1155/2014/469251","DOIUrl":"https://doi.org/10.1155/2014/469251","url":null,"abstract":"<p><p>Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor grade. Methods. We identified 123,780 cases of stages 1-3 primary female invasive breast cancer from California Cancer Registry. The surrogate classification was derived using ER/PR/HER2 and tumor grade. Kaplan-Meier survival analysis and Cox proportional hazards modeling were used to assess differences in survival and risk of mortality for the ER/PR/HER2 subtypes and surrogate classification within each stage. Results. The luminal B/HER2- surrogate classification had a higher risk of mortality than the luminal B/HER2+ for all stages of disease. There was no difference in risk of mortality between the ER+/PR+/HER2- and ER+/PR+/HER2+ in stage 3. With one exception in stage 3, the ER-negative subtypes all had an increased risk of mortality when compared with the ER-positive subtypes. Conclusions. Assessment of survival using ER/PR/HER2 illustrates the heterogeneity of HER2+ subtypes. The surrogate classification provides clear separation in survival and adjusted mortality but underestimates the wide variability within the subtypes that make up the classification. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"469251"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/469251","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32446644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-07-06DOI: 10.1155/2014/394696
Zohaib Khan, Justus Tönnies, Steffen Müller
Introduction. Smokeless tobacco is considered one of the major risk factors for oral cancer. It is estimated that over 90% of the global smokeless tobacco use burden is in South Asia. This paper aims to systematically review publications reporting epidemiological observational studies published in South Asia from 1984 till 2013. Methods. An electronic search in "Medline" and "ISI Web of Knowledge" yielded 734 publications out of which 21 were included in this review. All publications were assessed for quality using a standard quality assessment tool. Effect estimates (odds ratios (OR)) were abstracted or calculated from the given data. A random effects meta-analysis was performed to assess the risk of oral cancer with the use of different forms of smokeless tobacco. Results and Conclusion. The pooled OR for chewing tobacco and risk of oral cancer was 4.7 [3.1-7.1] and for paan with tobacco and risk of oral cancer was 7.1 [4.5-11.1]. The findings of this study suggest a strong causal link between oral cancer and various forms of smokeless tobacco. Public health policies in affected countries should consider SLT specific cessation programs in addition to campaigns and activities incorporated into smoking cessation programs.
介绍。无烟烟草被认为是口腔癌的主要风险因素之一。据估计,全球无烟烟草使用负担的 90% 以上发生在南亚。本文旨在系统回顾 1984 年至 2013 年在南亚发表的流行病学观察性研究报告。研究方法通过在 "Medline "和 "ISI Web of Knowledge "上进行电子检索,共获得 734 篇出版物,其中 21 篇被纳入本综述。使用标准质量评估工具对所有出版物进行了质量评估。从给定数据中抽取或计算出效果估计值(几率比(OR))。随机效应荟萃分析评估了使用不同形式的无烟烟草患口腔癌的风险。结果和结论。咀嚼烟草与口腔癌风险的汇总 OR 值为 4.7 [3.1-7.1],含烟草的派糖与口腔癌风险的汇总 OR 值为 7.1 [4.5-11.1]。本研究结果表明,口腔癌与各种形式的无烟烟草之间存在密切的因果关系。受影响国家的公共卫生政策除了考虑戒烟计划中的宣传和活动外,还应考虑针对无烟烟草的戒烟计划。
{"title":"Smokeless tobacco and oral cancer in South Asia: a systematic review with meta-analysis.","authors":"Zohaib Khan, Justus Tönnies, Steffen Müller","doi":"10.1155/2014/394696","DOIUrl":"10.1155/2014/394696","url":null,"abstract":"<p><p>Introduction. Smokeless tobacco is considered one of the major risk factors for oral cancer. It is estimated that over 90% of the global smokeless tobacco use burden is in South Asia. This paper aims to systematically review publications reporting epidemiological observational studies published in South Asia from 1984 till 2013. Methods. An electronic search in \"Medline\" and \"ISI Web of Knowledge\" yielded 734 publications out of which 21 were included in this review. All publications were assessed for quality using a standard quality assessment tool. Effect estimates (odds ratios (OR)) were abstracted or calculated from the given data. A random effects meta-analysis was performed to assess the risk of oral cancer with the use of different forms of smokeless tobacco. Results and Conclusion. The pooled OR for chewing tobacco and risk of oral cancer was 4.7 [3.1-7.1] and for paan with tobacco and risk of oral cancer was 7.1 [4.5-11.1]. The findings of this study suggest a strong causal link between oral cancer and various forms of smokeless tobacco. Public health policies in affected countries should consider SLT specific cessation programs in addition to campaigns and activities incorporated into smoking cessation programs. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"394696"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32563921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-09-17DOI: 10.1155/2014/865979
Md Jobayer Hossain, Li Xie, Suzanne M McCahan
Age at diagnosis is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL) survivorship. However, literature providing adequate assessment of the survival variability by age at diagnosis is scarce. The aim of this study is to assess the impact of this prognostic factor in pediatric ALL survival. We estimated incidence rate of mortality, 5-year survival rate, Kaplan-Meier survival function, and hazard ratio using the Surveillance Epidemiology and End Results (SEER) data during 1973-2009. There was significant variability in pediatric ALL survival by age at diagnosis. Survival peaked among children diagnosed at 1-4 years and steadily declined among those diagnosed at older ages. Infants (<1 year) had the lowest survivorship. In a multivariable Cox proportional hazard model stratified by year of diagnosis, those diagnosed in age groups 1-4, 5-9, 10-14, and 15-19 years were 82%, 75%, 57%, and 32% less likely to die compared to children diagnosed in infancy, respectively. Age at diagnosis remained to be a crucial determinant of the survival variability of pediatric ALL patients, after adjusting for sex, race, radiation therapy, primary tumor sites, immunophenotype, and year of diagnosis. Further research is warranted to disentangle the effects of age-dependent biological and environmental processes on this association.
诊断年龄是影响小儿急性淋巴细胞白血病(ALL)存活率的关键预后因素。然而,能够充分评估诊断年龄对存活率影响的文献却很少。本研究旨在评估这一预后因素对小儿急性淋巴细胞白血病存活率的影响。我们利用1973-2009年间的监测、流行病学和最终结果(SEER)数据估算了死亡率、5年生存率、卡普兰-梅耶生存函数和危险比。小儿 ALL 的存活率因诊断年龄的不同而存在很大差异。确诊年龄在1-4岁的儿童存活率最高,而确诊年龄较大的儿童存活率则稳步下降。婴儿
{"title":"Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis.","authors":"Md Jobayer Hossain, Li Xie, Suzanne M McCahan","doi":"10.1155/2014/865979","DOIUrl":"10.1155/2014/865979","url":null,"abstract":"<p><p>Age at diagnosis is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL) survivorship. However, literature providing adequate assessment of the survival variability by age at diagnosis is scarce. The aim of this study is to assess the impact of this prognostic factor in pediatric ALL survival. We estimated incidence rate of mortality, 5-year survival rate, Kaplan-Meier survival function, and hazard ratio using the Surveillance Epidemiology and End Results (SEER) data during 1973-2009. There was significant variability in pediatric ALL survival by age at diagnosis. Survival peaked among children diagnosed at 1-4 years and steadily declined among those diagnosed at older ages. Infants (<1 year) had the lowest survivorship. In a multivariable Cox proportional hazard model stratified by year of diagnosis, those diagnosed in age groups 1-4, 5-9, 10-14, and 15-19 years were 82%, 75%, 57%, and 32% less likely to die compared to children diagnosed in infancy, respectively. Age at diagnosis remained to be a crucial determinant of the survival variability of pediatric ALL patients, after adjusting for sex, race, radiation therapy, primary tumor sites, immunophenotype, and year of diagnosis. Further research is warranted to disentangle the effects of age-dependent biological and environmental processes on this association. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"865979"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32742033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-11-05DOI: 10.1155/2014/680126
Christina K Lettieri, Pamela Garcia-Filion, Pooja Hingorani
Desmoplastic small round cell tumor (DSRCT) is a rare but highly fatal malignancy. Due to the rarity of this neoplasm, no large population based studies exist. Procedure. This is a retrospective cohort analysis. Incidence rates were calculated based on sex and ethnicity and compared statistically. Gender-, ethnicity-, and treatment- based survival were calculated using the Kaplan-Meier method. Results. A total of 192 cases of DSRCT were identified. Peak incidence age was between 20 and 24 years. Age-adjusted incidence rate for blacks was 0.5 cases/million and for whites was 0.2 cases/million (P = 0.037). There was no statistically significant difference in survival based on gender or ethnicity. When adjusted for age, there was no statistically significant difference in survival amongst patients who received radiation therapy compared to those who did not (HRadj = 0.73; 95% CI 0.49, 1.11). There was a statistically significant survival advantage for patients who received radiation after surgery compared to those who did not (HR 0.49; 95% CI 0.30, 0.79). Conclusion. DSRCT is more common in males and in people of African-American descent. Although overall survival remains poor, radiation therapy following surgery seems to improve outcome in these patients.
结缔组织增生小圆细胞瘤(DSRCT)是一种罕见但高度致命的恶性肿瘤。由于这种肿瘤的罕见性,没有大规模的基于人群的研究存在。过程。这是一项回顾性队列分析。发病率根据性别和种族计算,并进行统计比较。使用Kaplan-Meier方法计算基于性别、种族和治疗的生存率。结果。共发现192例DSRCT。发病高峰年龄为20 ~ 24岁。黑人年龄调整后的发病率为0.5例/百万,白人为0.2例/百万(P = 0.037)。基于性别或种族的生存率没有统计学上的显著差异。经年龄调整后,接受放射治疗的患者与未接受放射治疗的患者的生存率无统计学意义差异(HRadj = 0.73;95% ci 0.49, 1.11)。术后接受放射治疗的患者与未接受放射治疗的患者相比有统计学上显著的生存优势(HR 0.49;95% ci 0.30, 0.79)。结论。DSRCT在男性和非裔美国人后裔中更为常见。尽管总体生存率仍然很低,但手术后放射治疗似乎改善了这些患者的预后。
{"title":"Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database.","authors":"Christina K Lettieri, Pamela Garcia-Filion, Pooja Hingorani","doi":"10.1155/2014/680126","DOIUrl":"https://doi.org/10.1155/2014/680126","url":null,"abstract":"<p><p>Desmoplastic small round cell tumor (DSRCT) is a rare but highly fatal malignancy. Due to the rarity of this neoplasm, no large population based studies exist. Procedure. This is a retrospective cohort analysis. Incidence rates were calculated based on sex and ethnicity and compared statistically. Gender-, ethnicity-, and treatment- based survival were calculated using the Kaplan-Meier method. Results. A total of 192 cases of DSRCT were identified. Peak incidence age was between 20 and 24 years. Age-adjusted incidence rate for blacks was 0.5 cases/million and for whites was 0.2 cases/million (P = 0.037). There was no statistically significant difference in survival based on gender or ethnicity. When adjusted for age, there was no statistically significant difference in survival amongst patients who received radiation therapy compared to those who did not (HRadj = 0.73; 95% CI 0.49, 1.11). There was a statistically significant survival advantage for patients who received radiation after surgery compared to those who did not (HR 0.49; 95% CI 0.30, 0.79). Conclusion. DSRCT is more common in males and in people of African-American descent. Although overall survival remains poor, radiation therapy following surgery seems to improve outcome in these patients. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"680126"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/680126","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32843429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-04-30DOI: 10.1155/2014/872029
Frank Buntinx, Christine Campbell, Marjan van den Akker
Part 1 Introduction: sickness and health in old age, R.E.Irvine epidemiology of cancer in the elderly, D.W.Lamont hopes and fears of the elderly cancer patient, I.B.Brewin. Part 2 Principles of management of cancer in the elderly: principles of surgery, Henry Tankel principles of radiotherapy, Thurston Brewin principles of chemotherapy, Craig Lewis, Kaye & Calman terminal care, J.Welsh. Part 3 Complications of cancer in the elderly: metabolic aspects, H.M.Hodkinson paraneoplastic CNS syndromes, Chen-Ya Huang. Part 4 Organs and systems: breast cancer, Allan Langlands bronchus lung tumours, Gordon P.Canning and F.J. Caird Oesophagus, P.T.D. Symonds stomach gastric cancers, Alan Jewkes, Simon Rowley and T.J. & Priestman colon, and rectum and anus, Philip F.Schofield liver, gallbladder, and pancreas, John Chalstrey kidney, ureter and bladder, Philip P.Clark cancer of the prostate, Malcolm A.Bagshaw gynaecological cancer malignancy, L.N.Hudson skin, Rona M.MacKie lymphoma and leukaemia and malignant, John M.Dagg myeloma, J.S.Malpas, Wallace Stewart eye ophthalmic neoplasia, Bertil E.Damato and Foulds malignant disorders of bone, Frank J.Frassica, Lester E.Wold and Franklin H. & Sim head and neck cancer, D.F.N.Harrison brain and spinal cord, David A.Stewart and F.J.Caird.
{"title":"Cancer in the elderly.","authors":"Frank Buntinx, Christine Campbell, Marjan van den Akker","doi":"10.1155/2014/872029","DOIUrl":"https://doi.org/10.1155/2014/872029","url":null,"abstract":"Part 1 Introduction: sickness and health in old age, R.E.Irvine epidemiology of cancer in the elderly, D.W.Lamont hopes and fears of the elderly cancer patient, I.B.Brewin. Part 2 Principles of management of cancer in the elderly: principles of surgery, Henry Tankel principles of radiotherapy, Thurston Brewin principles of chemotherapy, Craig Lewis, Kaye & Calman terminal care, J.Welsh. Part 3 Complications of cancer in the elderly: metabolic aspects, H.M.Hodkinson paraneoplastic CNS syndromes, Chen-Ya Huang. Part 4 Organs and systems: breast cancer, Allan Langlands bronchus lung tumours, Gordon P.Canning and F.J. Caird Oesophagus, P.T.D. Symonds stomach gastric cancers, Alan Jewkes, Simon Rowley and T.J. & Priestman colon, and rectum and anus, Philip F.Schofield liver, gallbladder, and pancreas, John Chalstrey kidney, ureter and bladder, Philip P.Clark cancer of the prostate, Malcolm A.Bagshaw gynaecological cancer malignancy, L.N.Hudson skin, Rona M.MacKie lymphoma and leukaemia and malignant, John M.Dagg myeloma, J.S.Malpas, Wallace Stewart eye ophthalmic neoplasia, Bertil E.Damato and Foulds malignant disorders of bone, Frank J.Frassica, Lester E.Wold and Franklin H. & Sim head and neck cancer, D.F.N.Harrison brain and spinal cord, David A.Stewart and F.J.Caird.","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"872029"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/872029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32380996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-01-02DOI: 10.1155/2014/239619
Richard M Hoffman, David K Espey, Robert L Rhyne, Melissa Gonzales, Ashwani Rajput, Shiraz I Mishra, S Noell Stone, Charles L Wiggins
Background. Previous analyses indicated that New Mexican Hispanics and American Indians (AI) did not experience the declining colorectal cancer (CRC) incidence and mortality rates observed among non-Hispanic whites (NHW). We evaluated more recent data to determine whether racial/ethnic differences persisted. Methods. We used New Mexico Surveillance Epidemiology and End Results data from 1995 to 2009 to calculate age-specific incidence rates and age-adjusted incidence rates overall and by tumor stage. We calculated mortality rates using National Center for Health Statistics' data. We used joinpoint regression to determine annual percentage change (APC) in age-adjusted incidence rates. Analyses were stratified by race/ethnicity and gender. Results. Incidence rates continued declining in NHW (APC -1.45% men, -1.06% women), while nonsignificantly increasing for AI (1.67% men, 1.26% women) and Hispanic women (0.24%). The APC initially increased in Hispanic men through 2001 (3.33%, P = 0.06), before declining (-3.10%, P = 0.003). Incidence rates declined in NHW and Hispanics aged 75 and older. Incidence rates for distant-stage cancer remained stable for all groups. Mortality rates declined significantly in NHW and Hispanics. Conclusions. Racial/ethnic disparities in CRC persist in New Mexico. Incidence differences could be related to risk factors or access to screening; mortality differences could be due to patterns of care for screening or treatment.
{"title":"Colorectal cancer incidence and mortality disparities in new Mexico.","authors":"Richard M Hoffman, David K Espey, Robert L Rhyne, Melissa Gonzales, Ashwani Rajput, Shiraz I Mishra, S Noell Stone, Charles L Wiggins","doi":"10.1155/2014/239619","DOIUrl":"10.1155/2014/239619","url":null,"abstract":"<p><p>Background. Previous analyses indicated that New Mexican Hispanics and American Indians (AI) did not experience the declining colorectal cancer (CRC) incidence and mortality rates observed among non-Hispanic whites (NHW). We evaluated more recent data to determine whether racial/ethnic differences persisted. Methods. We used New Mexico Surveillance Epidemiology and End Results data from 1995 to 2009 to calculate age-specific incidence rates and age-adjusted incidence rates overall and by tumor stage. We calculated mortality rates using National Center for Health Statistics' data. We used joinpoint regression to determine annual percentage change (APC) in age-adjusted incidence rates. Analyses were stratified by race/ethnicity and gender. Results. Incidence rates continued declining in NHW (APC -1.45% men, -1.06% women), while nonsignificantly increasing for AI (1.67% men, 1.26% women) and Hispanic women (0.24%). The APC initially increased in Hispanic men through 2001 (3.33%, P = 0.06), before declining (-3.10%, P = 0.003). Incidence rates declined in NHW and Hispanics aged 75 and older. Incidence rates for distant-stage cancer remained stable for all groups. Mortality rates declined significantly in NHW and Hispanics. Conclusions. Racial/ethnic disparities in CRC persist in New Mexico. Incidence differences could be related to risk factors or access to screening; mortality differences could be due to patterns of care for screening or treatment. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"239619"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/239619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32115235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01Epub Date: 2014-08-03DOI: 10.1155/2014/823484
Kevin A Henry, Recinda L Sherman, Kaila McDonald, Christopher J Johnson, Ge Lin, Antoinette M Stroup, Francis P Boscoe
Background. It remains unclear whether neighborhood poverty contributes to differences in subsite-specific colorectal cancer (CRC) incidence. We examined associations between census-tract poverty and CRC incidence and stage by anatomic subsite and race/ethnicity. Methods. CRC cases diagnosed between 2005 and 2009 from 15 states and Los Angeles County (N = 278,097) were assigned to 1 of 4 groups based on census-tract poverty. Age-adjusted and stage-specific CRC incidence rates (IRs) and incidence rate ratios (IRRs) were calculated. Analyses were stratified by subsite (proximal, distal, and rectum), sex, race/ethnicity, and poverty. Results. Compared to the lowest poverty areas, CRC IRs were significantly higher in the most impoverished areas for men (IRR = 1.14 95% CI 1.12-1.17) and women (IRR = 1.06 95% CI 1.05-1.08). Rate differences between high and low poverty were strongest for distal colon (male IRR = 1.24 95% CI 1.20-1.28; female IRR = 1.14 95% CI 1.10-1.18) and weakest for proximal colon. These rate differences were significant for non-Hispanic whites and blacks and for Asian/Pacific Islander men. Inverse associations between poverty and IRs of all CRC and proximal colon were found for Hispanics. Late-to-early stage CRC IRRs increased monotonically with increasing poverty for all race/ethnicity groups. Conclusion. There are differences in subsite-specific CRC incidence by poverty, but associations were moderated by race/ethnicity.
{"title":"Associations of census-tract poverty with subsite-specific colorectal cancer incidence rates and stage of disease at diagnosis in the United States.","authors":"Kevin A Henry, Recinda L Sherman, Kaila McDonald, Christopher J Johnson, Ge Lin, Antoinette M Stroup, Francis P Boscoe","doi":"10.1155/2014/823484","DOIUrl":"10.1155/2014/823484","url":null,"abstract":"<p><p>Background. It remains unclear whether neighborhood poverty contributes to differences in subsite-specific colorectal cancer (CRC) incidence. We examined associations between census-tract poverty and CRC incidence and stage by anatomic subsite and race/ethnicity. Methods. CRC cases diagnosed between 2005 and 2009 from 15 states and Los Angeles County (N = 278,097) were assigned to 1 of 4 groups based on census-tract poverty. Age-adjusted and stage-specific CRC incidence rates (IRs) and incidence rate ratios (IRRs) were calculated. Analyses were stratified by subsite (proximal, distal, and rectum), sex, race/ethnicity, and poverty. Results. Compared to the lowest poverty areas, CRC IRs were significantly higher in the most impoverished areas for men (IRR = 1.14 95% CI 1.12-1.17) and women (IRR = 1.06 95% CI 1.05-1.08). Rate differences between high and low poverty were strongest for distal colon (male IRR = 1.24 95% CI 1.20-1.28; female IRR = 1.14 95% CI 1.10-1.18) and weakest for proximal colon. These rate differences were significant for non-Hispanic whites and blacks and for Asian/Pacific Islander men. Inverse associations between poverty and IRs of all CRC and proximal colon were found for Hispanics. Late-to-early stage CRC IRRs increased monotonically with increasing poverty for all race/ethnicity groups. Conclusion. There are differences in subsite-specific CRC incidence by poverty, but associations were moderated by race/ethnicity. </p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2014 ","pages":"823484"},"PeriodicalIF":1.8,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32620692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}